Skip Navigation



European Heart Journal Advance Access published online on April 28, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi297
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
26/14/1358    most recent
ehi297v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van der Schouw, Y. T.
Right arrow Articles by Grobbee, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Schouw, Y. T.
Right arrow Articles by Grobbee, D. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; All rights reserved
Received December 1, 2004
Revised January 31, 2005
Accepted March 24, 2005

Current opinion

Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy

Yvonne T. van der Schouw 1* and Diederick E. Grobbee 1

1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Room STR 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands

* To whom correspondence should be addressed.
Yvonne T. van der Schouw, E-mail: y.t.vanderschouw{at}umcutrecht.nl


  Abstract

There is a large discrepancy between the findings of observational and experimental studies on the effects of post-menopausal hormone therapy (HT) and coronary heart disease risk. Observational studies, mainly comprising peri-menopausal women, report risk reductions up to 30-50%, whereas the experimental studies, comprising elderly women, do not show coronary protection. Suggested explanations are methodological differences, such as confounding or healthy user bias, incomplete capture of early events, the stage of atherosclerosis at the start of HT, formulation or dose of HT, or early susceptibility to thrombotic events. We propose that the presence of climacteric complaints determines the susceptibility to hormone replacement therapy. Climacteric complaints are the main indication for HT in the population, whereas in the clinical trials women with climacteric complaints were either explicitly excluded or comprised only a minority of the total randomized population. There is some, albeit circumstantial evidence to support this hypothesis. Women with climacteric complaints of sweating not only appear to have lower levels of serum oestradiol, but also lose more bone than women without climacteric complaints. Consequently, sweating episodes may indicate potential benefits from HT. It has also been reported that hot flushes during menopause correlate with a higher level of oxidative stress and an increased cardiovascular reactivity to stressful situations. We suggest epidemiological approaches to test our hypothesis.

Keywords: Hot flushes; Post-menopausal hormone therapy; Post-menopausal women; Cardiovascular diseases; Menopausal complaints.
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
G.-C. M. Gast, D. E. Grobbee, V. J.M. Pop, J. J. Keyzer, C. J.M. Wijnands-van Gent, G. N. Samsioe, P. M. Nilsson, and Y. T. van der Schouw
Menopausal Complaints Are Associated With Cardiovascular Risk Factors
Hypertension, June 1, 2008; 51(6): 1492 - 1498.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, A. G. Uitterlinden, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils
Influence of Estrogen Receptor {alpha} and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 462 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Grohe
'Tib the balance': the search for the optimal hormone replacement therapy
Eur. Heart J., July 2, 2005; 26(14): 1345 - 1346.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.